Cistanche deserticola polysaccharides protect against cyclophosphamide-induced premature ovarian failure in mice by regulating the JAK-STAT pathway
article
OA: closed
CC0
AI-generated summary
Cistanche deserticola polysaccharides protected mice against cyclophosphamide-induced premature ovarian failure by regulating the JAK-STAT pathway.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Ethnopharmacological relevanceClassical Chinese medical texts, notably the Compendium of Materia Medica (Ben Cao Gang Mu) and Zhong Hua Ben Cao (Chinese Herbal Medicine), have historically documented Cistanche deserticola's application as a tonic herb for addressing reproductive disorders including male impotence, reduced fertility and female menstrual infertility, among other conditions. Polysaccharides from Cistanche deserticola are recognized as the plant's principal bioactive components. Nevertheless, the therapeutic potential and mechanistic actions of Cistanche deserticola polysaccharides (CDPs) in premature ovarian failure (POF) remain unexplored.Aim of the studyThis study aimed to determine the protective role of CDPs in POF and to elucidate the underlying mechanisms.Material and methodsPOF mouse models were developed through intraperitoneal administration of cyclophosphamide (CTX) at a high dose of 120 mg/kg/day and followed by 8 mg/kg/day (low maintenance dose) administered daily for 14 consecutive days. In a prophylactic therapeutic regimen, CDPs received pre-treatment initiation two weeks before model establishment, with phased administration maintained throughout three distinct temporal parameters (2-, 6-, and 8-week intervals) during pharmacological intervention. Upon anesthetization of the mice, ovarian tissues were collected for subsequent histopathological and molecular investigations. These analyses included immunohistochemistry to detect apoptotic proteins, Proliferative index mapping through Ki67 immunofluorescence, and electron microscopy to assess mitochondrial status and other pertinent indicators. RNA-seq elucidated the core regulatory pathway governing POF and potential protective targets for CDPs.ResultsExperimental evidence established that intragastric administration of CDPs ameliorate histopathological ovarian lesions and rescue endocrine homeostasis, thereby enhancing the health of offspring in CTX-induced POF mice. This effect is facilitated by the promotion of follicular development, the proliferation of follicles, and the suppression of granulosa cell apoptosis. Furthermore, CDPs significantly attenuation of oxidative stress via ROS scavenging and restore mitochondrial morphology and function. In conclusion, the protective role of CDPs are closely linked to the JAK-STAT signaling pathway in POF models.ConclusionOur findings demonstrate that CDPs are capable of protecting protect the ovary tissue against CTX-induced damages through suppression of the activation of the JAK-STAT pathway and attenuation of granulosa cells (GCs) apoptosis.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (2)
References (58)
- Cilostazol protects against cyclophosphamide-induced ovarian toxicity in female rats: role of cAMP and HO-1 via openalex
- Mitochondrial Function in Modulating Human Granulosa Cell Steroidogenesis and Female Fertility via openalex
- doi:10.1016/j.ejmech.2022.114892 via openalex
- doi:10.1016/j.phymed.2021.153471 via openalex
- doi:10.1080/15548627.2020.1847444 via openalex
- W1540046929 via openalex
- doi:10.1016/j.lfs.2023.121789 via openalex
- doi:10.1152/ajpheart.00944.2009 via openalex
- doi:10.1186/s13287-021-02529-w via openalex
- doi:10.1016/j.jep.2022.115495 via openalex
- doi:10.1186/s13287-022-03012-w via openalex
- doi:10.3322/caac.21637 via openalex
- doi:10.1007/s00210-020-01975-2 via openalex
- doi:10.1038/nature12985 via openalex
- doi:10.1186/1750-1172-1-9 via openalex
- doi:10.1073/pnas.1017213108 via openalex
- doi:10.1038/s41467-021-22829-2 via openalex
- doi:10.1016/j.jtcme.2023.02.004 via openalex
- doi:10.3389/fphar.2022.810524 via openalex
- doi:10.3389/fendo.2023.1077315 via openalex
- doi:10.1186/s13287-023-03297-5 via openalex
- doi:10.1111/jcmm.15038 via openalex
- doi:10.1039/d2fo00008c via openalex
- doi:10.1038/s41467-022-28611-2 via openalex
- doi:10.1111/j.1471-0528.1989.tb03383.x via openalex
- doi:10.18632/aging.203090 via openalex
- doi:10.1016/j.jep.2024.117782 via openalex
- doi:10.2139/ssrn.4661484 via openalex
- doi:10.1186/s13287-024-03926-7 via openalex
- doi:10.1002/cncr.35444 via openalex
- doi:10.1002/jcc.27280 via openalex
- doi:10.1016/j.phymed.2024.155681 via openalex
- doi:10.1016/j.maturitas.2024.107922 via openalex
- W6632457018 via openalex
- W6809162660 via openalex
- W6846249278 via openalex
- W6850580837 via openalex
- doi:10.1186/s13048-024-01498-x via openalex
- doi:10.1016/j.mce.2024.112280 via openalex
- doi:10.1021/acsomega.3c09551 via openalex
- doi:10.1093/humupd/dmz027 via openalex
- doi:10.3389/fphys.2023.1113684 via openalex
- doi:10.1001/jamaoncol.2015.3251 via openalex
- doi:10.1038/s41598-024-51990-z via openalex
- doi:10.6004/jnccn.2023.0031 via openalex
- doi:10.1016/j.redox.2019.101110 via openalex
- doi:10.1016/j.jep.2022.115842 via openalex
- doi:10.1016/s0140-6736(02)11032-4 via openalex
- doi:10.1177/1535370217693323 via openalex
- doi:10.1186/s13058-024-01822-9 via openalex
- doi:10.3389/fphar.2016.00289 via openalex
- doi:10.1016/j.gene.2016.10.011 via openalex
- doi:10.1016/j.steroids.2003.09.003 via openalex
- doi:10.1186/s13048-023-01278-z via openalex
- doi:10.18632/aging.204320 via openalex
- doi:10.1186/s13048-020-00739-z via openalex
- doi:10.1016/j.chroma.2008.07.031 via openalex
- doi:10.1093/pnasnexus/pgad055 via openalex
Source provenance
- openalex
- last seen: 2026-05-11T06:53:11.423351+00:00
License: CC0
· commercial use OK